- Home
- FATE vs ACRS Comparison
FATE vs ACRS Comparison
Compare FATE & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- ACRS
- Stock Information
- Founded
- FATE 2007
- ACRS 2012
- Country
- FATE United States
- ACRS United States
- Employees
- FATE N/A
- ACRS N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- ACRS Health Care
- Exchange
- FATE Nasdaq
- ACRS Nasdaq
- Market Cap
- FATE 177.7M
- ACRS 165.7M
- IPO Year
- FATE 2013
- ACRS 2015
- Fundamental
- Price
- FATE $1.14
- ACRS $1.59
- Analyst Decision
- FATE Hold
- ACRS Strong Buy
- Analyst Count
- FATE 7
- ACRS 9
- Target Price
- FATE $3.83
- ACRS $9.25
- AVG Volume (30 Days)
- FATE 1.9M
- ACRS 1.3M
- Earning Date
- FATE 08-12-2025
- ACRS 08-06-2025
- Dividend Yield
- FATE N/A
- ACRS N/A
- EPS Growth
- FATE N/A
- ACRS N/A
- EPS
- FATE N/A
- ACRS N/A
- Revenue
- FATE $13,335,000.00
- ACRS $17,777,000.00
- Revenue This Year
- FATE N/A
- ACRS N/A
- Revenue Next Year
- FATE N/A
- ACRS $11.77
- P/E Ratio
- FATE N/A
- ACRS N/A
- Revenue Growth
- FATE 105.85
- ACRS N/A
- 52 Week Low
- FATE $0.66
- ACRS $1.05
- 52 Week High
- FATE $5.92
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- FATE 46.69
- ACRS 59.88
- Support Level
- FATE $1.05
- ACRS $1.44
- Resistance Level
- FATE $1.18
- ACRS $1.52
- Average True Range (ATR)
- FATE 0.08
- ACRS 0.10
- MACD
- FATE -0.00
- ACRS 0.00
- Stochastic Oscillator
- FATE 54.76
- ACRS 79.17
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.